[Assessment of a year's systematic use in cancer of the otorhinolaryngological area of a new antimitotic: bleomycin. Study of 209 patients].
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003035:Cobalt / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D007269:Injections, Intra-Arterial; D007273:Injections, Intramuscular; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008171:Lung Diseases / Q000139:chemically induced; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D012877:Skin Manifestations
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D003035:Cobalt
Etude à un an d'une utilisation systématisée d'uun nouvel antimitotique: al bléomycine sur les cancers de la sphère O.R.L. Etude sur 209 malades.